Project Grant R41NS120748

Award Date 9/1/21
Completion Date 8/31/22
Dollars Obligated $1M
Federal Grant Program
93.372
Assistance Type
Project Grant
Place of Performance
Colorado, USA
Similar Awards
Regulonix LLC was awarded a $1,258,410 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), to support research under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). Through this one-year award ending August 31, 2022, Regulonix will partner with the University of Arizona to characterize inhibitors of the neuropilin-1 (NRP-1) receptor for potential...
This federal Project Grant award of $738,566 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to define the circuit mechanisms that regulate somatosensory feedback in the brain. The research aims to determine if similar regulatory mechanisms exist to modulate somatosensory signals across the body and different sensory modalities, and how...
This $429,000 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research to investigate the role of Schwann cell PIEZO1 in pain sensation. The key objectives are to: 1) develop and validate adeno-associated virus (AAV) vectors for selective inhibition of Schwann cell PIEZO1, and 2) determine the sensory effects of Schwann cell...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $446,875.00 to generate and characterize a new NTRK3-FLPO mouse line. This transgenic mouse model will allow researchers to genetically label and manipulate mouse A-beta nociceptors, an important population of primary sensory neurons involved in mechanical pain...
This $273,254 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research focused on understanding how the brain processes sensory information from rhythmic movements, such as whisking in rodents. The research aims to elucidate the neural computations underlying active sensing, with a focus on how the thalamocortical and recurrent...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $459,097 to Pison Technology, Inc. to assess the company's neural biosensor as a scalable digital biomarker for characterizing disease progression in amyotrophic lateral sclerosis (ALS). The goal is to develop a wearable device that can remotely monitor physiological data from...
The Salk Institute for Biological Studies was awarded a $4,090,484 Project Grant from the National Institute of Neurological Disorders and Stroke under the 21st Century Cures Act - Brain Research through Advancing Innovative Neurotechnologies program. The grant will support development of a novel quantitative technique to monitor presynaptic release of neuropeptides from terminals in awake, behaving mice. Specifically, the Institute will develop a sensor to detect release of dense-core...
This Project Grant award, with the ID R21NS137066, was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program. The award will support research to investigate the role of the mesocortical glutamatergic pathway, connecting the ventral tegmental area (VTA) to the prefrontal cortex (PFC), in the development and maintenance of chronic neuropathic pain....
This $1,836,842 Project Grant from the National Institute of Neurological Disorders and Stroke will support research into sensory-motor strategies for odor-guided navigation. Funded under the Extramural Research Programs in the Neurosciences and Neurological Disorders program, the Trustees of Boston University will conduct research to better understand how spatial information is encoded in the olfactory bulb during odor-guided search behaviors in mice. Researchers will use new imaging tools to...
The National Institute of Neurological Disorders and Stroke (NINDS), through the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), awarded Versapeutics Inc. a $2,380,552 federal project grant on September 18, 2023 to conduct toxicology and efficacy studies of their novel antibody therapeutic Versamab-101 for treating spinal cord injury. Versapeutics, a for-profit biotechnology company, will utilize the funding to evaluate the safety profile and determine...

Vulintus, Inc. was awarded a $1,025,456 Project Grant from the National Institute of Neurological Disorders and Stroke within the Department of Health and Human Services to develop the SensiTrak system. The grant was funded under the 21st Century Cures Act Brain Research through Advancing Innovative Neurotechnologies program.

Under this award, Vulintus will create an automated, high-throughput behavioral testing platform to precisely measure somatosensory function in rodent models. Current methods often rely on withdrawal responses to unpleasant stimuli, which can be stressful for animals and yield high variability. SensiTrak aims to support complex, electromechanical interactions with trained, voluntary animal behaviors through interchangeable task modules, peripherals, and open-source software. In the initial phase, Vulintus will finalize the SensiTrak prototype design, conduct bench testing, and validate the system using a rat model of somatosensory impairment. The grant period runs from September 1, 2021 through August 31, 2022.

Generated 1/6/24, 10:47 AM